There are currently 441 clinical trials in Las Vegas, Nevada looking for participants to engage in research studies. Trials are conducted at various facilities, including Comprehensive Cancer Centers of Nevada, University Medical Center of Southern Nevada, Summerlin Hospital Medical Center and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
NCT03650114
Recruiting
The purpose of this study is to collect long-term safety, tolerability, effectiveness and health outcomes data in eligible subjects who have participated in a Novartis ofatumumab clinical MS study. Vaccination sub-study The purpose of this research sub-study is to find out the effects of ofatumumab on the development of antibody responses to selected vaccines and keyhole limpet hemocyanin (KLH) neo-antigen in subjects with relapsing multiple sclerosis (RMS).
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
05/21/2024
Locations: Cleveland Clinic Foundation, Las Vegas, Nevada
Conditions: Relapsing Multiple Sclerosis
Register for Updates
GEMINI-NSCLC: NSCLC Biomarker Study
NCT05236114
Recruiting
Non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/21/2024
Locations: OptumCare Cancer Care, Las Vegas, Nevada
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10)
NCT04944979
Recruiting
The purpose of this study is to assess efficacy, safety and pharmacokinetics of Kedrion Immunoglobulin 10% (KIg10) in pediatric patients with Primary Immunodeficiency Disease (PID).
Gender:
All
Ages:
Between 2 years and 16 years
Trial Updated:
05/21/2024
Locations: Alliance for Childhood Diseases dba Cure 4 The Kids Foundation, Las Vegas, Nevada
Conditions: Primary Immunodeficiency Disease
Register for Updates
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
NCT04092673
Recruiting
This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of Zotatifin (eFT226) in subjects with selected advanced solid tumor malignancies.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/20/2024
Locations: Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada
Conditions: Solid Tumor, Adult
Register for Updates
A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
NCT05499130
Recruiting
The primary objective is to characterize the efficacy TEV-48574 in adult participants with IBD (moderate to severe Ulcerative Colitis (UC) or Crohn's Disease (CD)) as assessed by induction of clinical remission (UC) and endoscopic response (CD) at week 14. Secondary objectives: To evaluate the efficacy and dose response of the 2 different dose regimens as assessed by multiple standard measures To evaluate the safety and tolerability of the 2 different dose regimens To evaluate the immunogenici... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/20/2024
Locations: Teva Investigational Site 15369, Las Vegas, Nevada
Conditions: Crohn Disease, Colitis, Ulcerative
Register for Updates
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma
NCT03656536
Recruiting
The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/20/2024
Locations: Comprehensive Cancer Centers of Nevada-Twain, Las Vegas, Nevada
Conditions: Unresectable Cholangiocarcinoma, Metastatic Cholangiocarcinoma
Register for Updates
Post-Market Registry of the Patient Experience When Using UltraGuideCTR for Carpal Tunnel Release
NCT06071468
Recruiting
Multicenter prospective registry of patients with symptomatic Carpal Tunnel Syndrome treated with Ultrasound Guided Carpal Tunnel Release (CTR-US).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/20/2024
Locations: Hand Center of Nevada, Las Vegas, Nevada
Conditions: Carpal Tunnel Syndrome, CTS
Register for Updates
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
NCT03742102
Recruiting
This study is designed to determine the efficacy and safety of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple negative breast cancer
Gender:
Female
Ages:
Between 18 years and 130 years
Trial Updated:
05/20/2024
Locations: Research Site, Las Vegas, Nevada
Conditions: Triple Negative Breast Neoplasms
Register for Updates
Clinical Data Registry of Amblyopia Patients on Luminopia Treatment
NCT06429280
Recruiting
Amblyopia is the most prevalent cause of reduced monocular visual acuity in children and young adults, with estimates of prevalence ranging from 1% to 5%. The most common associated amblyogenic risk factors are uncorrected anisometropia, strabismus, or a combination of these. In addition to reduced visual acuity, amblyopic patients may also have measurable dysfunction of accommodation, fixation, binocularity, vergence, reading fluency, depth perception, and contrast sensitivity. For the first t... Read More
Gender:
All
Ages:
All
Trial Updated:
05/20/2024
Locations: Nevada Eye Physicians, Las Vegas, Nevada
Conditions: Amblyopia
Register for Updates
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
NCT05997017
Recruiting
A Phase 2 Multi-center Open-label Trial of nab-Sirolimus in Combination with Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer
Gender:
All
Ages:
18 years and above
Trial Updated:
05/20/2024
Locations: Women's Cancer Center of Nevada, Las Vegas, Nevada
Conditions: Endometrial Cancer, Endometrioid Tumor, Cancer, Tumor, Recurrent Endometrial Carcinoma, Endometrioid Endometrial Cancer
Register for Updates
Optilume PoST AppRoval Clinical Evaluation of Andrology ParaMeters
NCT05383274
Recruiting
Single-arm, prospective study assessing semen quality after treatment with the Optilume Urethral DCB in men between 22 and 65 years of age.
Gender:
Male
Ages:
Between 22 years and 65 years
Trial Updated:
05/17/2024
Locations: Freedman Urology, Las Vegas, Nevada
Conditions: Urethral Stricture
Register for Updates
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
NCT03165734
Recruiting
This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician's choice (P/C) therapy in patients with MF and severe thrombocytopenia (platelet count <50,000/μL). Approximately 399 patients in total will be enrolled, randomized 2:1 to either pacritinib (approximately 266 patients) or to P/C therapy (approximately 133 patients) Condition or disease: Primary Myelofibrosis/Post-Polycythemia Vera Myelofibrosis/ Post-essential Thrombo... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/16/2024
Locations: Comprehensive Cancer Centers of Nevada- Twain Office, Las Vegas, Nevada
Conditions: Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Register for Updates